Description:

The Third Coast CFAR’s Clinical Sciences Core will lead a virtual workshop disseminating findings from REPRIEVE, a global study that evaluated the efficacy of a statin to prevent cardiovascular disease among people with HIV. The event will feature principal investigators of clinical studies on cardiovascular complications in HIV and an interactive panel discussion with world renowned experts on HIV research, cardiology, and epidemiology.

Introduction:

Babafemi Taiwo, MBBS
Director, TC CFAR Clinical Sciences Core
Gene Stollerman Professor of Medicine, Chief of Infectious Diseases, Northwestern University

REPRIEVE Highlights and Perspectives on Clinical Impact:

Steven Grinspoon, MD
Professor of Medicine, Harvard Medical School
Chief of the Metabolism Unit, Massachusetts General Hospital
Co-Principal Investigator, Clinical Coordinating Center, REPRIEVE
Peter Hunt, MD
Professor of Medicine, Division of Experimental Medicine, University of California San Francisco (UCSF)
Co-Director, UCSF-Bay Area Center for AIDS Research

Moderated Panel Discussion:

Panelists

Amesika Nyaku, MD, MS
Assistant Professor, Division of Infectious Diseases, Rutgers New Jersey Medical School
Frank J. Palella Jr., MD
Director, Center for HIV and Aging, Potocsnak Family Longevity Institute
Potocsnak Family Professor of Medicine, Division of Infectious Diseases, Northwestern University
Matthew Feinstein, MD, MSc
Director, Clinical and Translational Immunocardiology Program
Associate Professor of Medicine, Division of Cardiology, Northwestern University

Moderator

Jennifer Jao, MD, MPH
Co-Director, TC CFAR Clinical Sciences Core
Susan B. DePree Founders’ Board Professor in Pediatric, Adolescent, and Maternal HIV Infection
Director, Section of Pediatric, Adolescent, and Maternal HIV Infection, Ann & Robert H. Lurie Children’s Hospital of Chicago

Learning Objectives:

Discuss how the REPRIEVE trial’s findings will impact clinical practice.
Consider the implementation of broader use of statins for people living with HIV.
Gain insight on current clinical studies available within the REPREIVE trial and how attendees can collaborate across institutions to participate.
Review availability of data and specimens from the REPRIEVE trial to support new research.